MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma.
miRNAs have been reported to be involved in the pathogenesis of many cancers. In this article, we investigated the role and the mechanisms of miR-15a/16 in the pathogenesis of multiple myeloma (MM). We found that miR-15a/16 was down-regulated in bone marrow-derived mononuclear cells (BM-MNCs) of newly diagnosed patients with MM and the downregulation of miR-15a/16 was correlated with International Staging System (ISS) stage. We then demonstrated miR-15a/16 inhibited myeloma cells proliferation, and increased apoptosis rate of U266 cells by suppressing the expression of anti-apoptosis protein Bcl-2. We also found miR-15a/16 could decrease VEGF-A and IL-17 levels in the supernatant of myeloma cells. These results indicate that miR-15a/16 may function as a tumor suppressor in MM through multiple regulatory mechanisms and they may be potential targets for the therapy of MM.
Laboratory Center of Diagnostics, Xuzhou Medical University.
Yanjie
Y
Li
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Bingyun
B
Zhang
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Wenjing
W
Li
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Lijin
L
Wang
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Zhiling
Z
Yan
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Hujun
H
Li
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Yao
Y
Yao
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Ruosi
R
Yao
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University.
Kailin
K
Xu
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University; Institute of Hematology, Xuzhou Medical University. Electronic address: lizhenyumd@163.com.
Zhenyu
Z
Li
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007109:Immunity; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D035683:MicroRNAs / Q000235:genetics / Q000502:physiology*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology*; D009389:Neovascularization, Pathologic; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
D020381:Interleukin-17; C505361:MIRN15 microRNA, human; C505362:MIRN16 microRNA, human; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D042461:Vascular Endothelial Growth Factor A
Bcl-2; IL-17; Multiple myeloma; VEGF-A; miR-15a/16